Aristotle University Of Thessaloniki (AUTH)
Το φαινόμενο της ινκρετίνης σε γυναίκες με σύνδρομο πολυκυστικών ωοθηκών
Abstract
dc:descriptionPolycystic ovarian syndrome (PCOS) is a common endocrine disorder, affecting nearly 10% of reproductive age women. It is characterized by a clustering of oligo/anovulation, clinical and/or biochemical hyperadrogenism and polycystic ovaries. The pathophysiology of PCOS is complex, involving the hypothalamus- pituitary- ovarian axis, ovarian theca cell hyperplasia, insulin resistance (IR), and a multitude of other cytokine- and adipocyte- driven factors. Approximately 50% of PCOS women are overweight or obese and many metabolic abnormalities, such as dyslipidemia and hyperglycemia, are inconsistently present in the majority of these patients. Women with PCOS also demonstrate increased risk of diabetes mellitus (DM) type 2 and accumulation of cardiovascular disease (CVD) risk factors. Insulin resistance is considered to play an important role both in the pathogenesis of PCOS and the progression to DM. In normal subjects, 65-70% of the glucose - dependent insulin secretion is attributed to the incretin effect of the gastrointestinal hormones, glucose dependent insulinotropic peptide (GIP) and glucagon like peptide-1 (GLP-1). Several studies have focused on the investigation of the relationship between incretin secretion and beta cell function in PCOS. However more recent data provide conflicting results on the incretin secretion pattern in PCOS in relation to BMI of the participants. Despite this inconsistency in the results regarding the incretin response, its possible contribution in insulin hypersecretion observed in PCOS patients remains intriguing. Twenty consecutive women with PCOS (ten obese and ten lean) and ten age-matched healthy female (five lean and five obese) were recruited from the University outpatient clinic. Two tests, oral glucose tolerance test (oGTT) and isoglycemic test, were carried out on each participant after an overnight fast at 2-weeks interval. Age, lipid profile, insulin sensitivity (QUICKI), SHBG, TSH and baseline GIP values did not differ between the PCOS and the control groups. However, the basal GLP-1 concentrations were significantly lower in the obese PCOS women compared to both the control (p= 0.023) and the lean PCOS women (p= 0.02). Free testosterone, Δ₄ - androstenedione and DHEAS were significantly higher in PCOS women (both obese and lean) compared to controls. No significant difference between groups was detected in fasting glucose, insulin and C-peptide levels. Similarly, there was no significant difference between the control group and the PCOS in the AUC for insulin, C-peptide and GLP-1 in response to oGTT. However, GIP response differed between PCOS and control groups (p=0.018), since obese PCOS demonstrated lower GIP concentrations (AUC) in response to oGTT compared to the control group (p=0.029). When exploring responses to isoglycemic test (sparing incretin influence on insulin secretion), no difference was detected between PCOS and control group in the AUC’s for insulin, C-peptide, GIP and GLP-1. The Incretin effect (IE) was calculated from both total insulin and C-peptide secretion. Although analysis failed to detect any significant difference in IE when calculated on the basis of insulin, it revealed statistical significance when C-peptide was used for calculations. IE was found to be significantly augmented in the obese women with PCOS compared to controls (p=0.011). Women with PCOS (both lean and obese) exhibited a non- significant increase in insulin and C-peptide levels during the 3h oGTT compared to control group, despite similar glucose levels between the groups. The observed increased insulinotropic effect could counteract the blunted GIP response to oGTT in obese women with PCOS and partly explain the unaffected insulin secretion that we, as well as others have noticed in this study population. It is not clear whether this apparent increase in the sensitivity of pancreatic beta cells to the incretin stimulation can be attributed to a primary pathology of PCOS or other potentially confounding factors such as obesity, regardless of the presence of insulin resistance, exert an additive action in this phenomenon.
Degree
thesis:*- Grantor dc:publisher
- Aristotle University Of Thessaloniki (AUTH)
- Year dc:date
- 2010
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Pontikis, Charalampos
- Ποντίκης, Χαράλαμπος
Subjects
dc:subject × 18- Σύνδρομο πολυκυστικών ωοθηκών
- Υπερανδρογοναιμία
- Ανοωθυλακιορρησία
- Φαινόμενο ινκρετίνης
- Ινκρετίνες
- Γλυκοζοεξαρτώμενο ινσουλινότροπο πεπτίδιο
- Πεπτίδιο προσομοιάζων με το γλουκαγόνο-1
- Polycystic ovary syndrome (PCOS)
- Hyperandrogenism
- Anovulation
- Incretin effect
- Incretins
- GIP
- GIP-1
- Ιατρική και Επιστήμες Υγείας
- Κλινική Ιατρική
- Medical and Health Sciences
- Clinical Medicine
Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/19457